Leading Growth Driver in the Drug Discovery Market in 2025: Healthcare Expenditure Surge Boosts Drug Discovery Market Driver's Influence

What market dynamics are playing a key role in accelerating the growth of the drug discovery market?
The growth of the drug discovery market is being fuelled by increasing healthcare expenditure. Nations globally are allocating a significant portion of their GDP towards healthcare costs encompassing hospital care, physician, clinical and professional services, dental care, other health and personal care, home healthcare, nursing facilities, retirement communities, prescription drugs and more. Drug discovery plays a crucial role in healthcare spending as it is indispensable for disease treatment and lifespan extension. The demand for new medications to combat emerging diseases is surging. To cite an example, the Centers for Medicare and Medicaid Services, a US federal agency, reported in October 2024 that national health expenditure rose by 4.1% to $4.5 trillion in 2022, or $13,493 per person from 2023-32. The average national health expenditure growth (5.6%) is forecasted to surpass average GDP growth (4.3%), leading to a rise in the proportion of healthcare spending from 17.3% of GDP in 2022 to 19.7% in 2032. Hence, escalated healthcare costs are fostering the development of the drug discovery market.

Get Your Drug Discovery Market Report Here:
https://www.thebusinessresearchcompany.com/report/drug-discovery-global-market-report

How will the growth rate of the drug discovery market shape industry trends by 2034?
In recent times, the size of the drug discovery market has expanded swiftly. With an expected rise from $110.26 billion in 2024 to $125.23 billion in 2025, it exhibits a compound annual growth rate (CAGR) of 13.6%. The growth witnessed historically can be linked to developments in genomics and proteomics, an increasing incidence of chronic ailments, and the advent of biopharmaceuticals.

The market size for drug discovery is predicted to experience a swift expansion in the coming years, escalating to an estimated $221.71 billion in 2029, with a compound annual growth rate (CAGR) of 15.3%. The increase during the forecast period can be linked to the incorporation of precision medicine, attention to rare diseases, and the development of personalized therapies. Notable trends forecasted include the collaboration of drug discovery models, a concentrated focus on rare diseases and orphan drugs, the amalgamation of multi-omics data, the quick uptake of organoids and 3D cell culture models, and the progress in virtual screening.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=7746&type=smp

What trends are poised to drive the future success of the drug discovery market?
Advancements in technology are playing a significant role in transforming the drug discovery market. Firms active in this sector are introducing diverse new technologies including AI, imaging technology, amongst others, to expedite the drug discovery process. The utilization of imaging technology allows the visualization, characterization, and quantification of non-invasive biological actions within organisms as a reaction to medications. Techniques that leverage the potential of either probes or tissue are essential for disease understanding and development of new treatments. For instance, in May 2023, Google Cloud introduced two innovative AI-based tools, the Target and Lead Identification Suite, and the Multiomics Suite. These tools are meant to aid biotech and pharmaceutical companies in advancing drug discovery and precision medicine. The Target and Lead Identification Suite helps in determining the function of proteins and amino acids, while the Multiomics Suite expedites the unveiling and understanding of genomic data, thus, playing a pivotal role in creating precision treatments.

Which primary segments of the drug discovery market are driving growth and industry transformations?
The drug discovery market covered in this report is segmented -

1) By Drug Type: Small Molecule, Large Molecule
2) By Process: Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, Candidate Validation
3) By Technology: High Throughput Screening, Spectroscopy, Combinatorial Chemistry, Biochips, Pharmacogenomics And Pharmacogenetics, Bioinformatics, Metabolomics, Nanotechnology, Other Technologies
4) By Therapeutic Area: Oncology, Neurology, Infectious And Immune System Diseases, Digestive System Diseases, Cardiovascular Diseases, Diabetes, Respiratory Disease, Other Therapeutic Areas
5) By End User: Pharmaceutical Companies, CROs, Other End-Users

Subsegments:
1) By Small Molecule: Synthetic Small Molecules, Natural Small Molecules, Targeted Small Molecule Drugs
2) By Large Molecule: Monoclonal Antibodies, Proteins And Peptides, Nucleic Acid-Based Therapies

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7746

Which geographical regions are pioneering growth in the drug discovery market?
North America was the largest region in the drug discovery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the influential players reshaping the drug discovery market landscape?
Major companies operating in the drug discovery market include Pfizer Inc., Merck & Co. Inc., Novartis International AG, Thermo Fisher Scientific Inc., WuXi AppTec Group, GlaxoSmithKline plc, Eli Lilly and Company, Laboratory Corporation of America Holdings, Evotec SE, Eurofins Scientific SE, Agilent Technologies Inc., Sanofi S.A., Charles River Laboratories International Inc., Pharmaron Ltd., Viva Biotech Ltd., Albany Molecular Research Inc., Schrödinger Inc., BioDuro Ltd., Aptuit LLC, Selvita S.A., Sygnature Discovery Limited, Jubilant Biosys Limited, Gero Limited, Domainex Ltd., Verge Genomics lnc., Aqemia SAS, BenevolentAI Limited, EPIVAX INC., ProteinQure lnc., Synlogic Inc., ChemPartner Co. Ltd., WuXi Biologics lnc., Abzena plc, Lonza Group Ltd., Catalent lnc., Recursion Pharmaceuticals Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=7746&type=smp

What Is Covered In The Drug Discovery Global Market Report?

•Market Size Forecast: Examine the drug discovery market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the drug discovery market for a structured understanding.
•Key Players Overview: Analyze major players in the drug discovery market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the drug discovery market.
•Segment Contributions: Evaluate how different segments drive overall growth in the drug discovery market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the drug discovery market.
•Industry Challenges: Identify potential risks and obstacles affecting the drug discovery market.
•Competitive Landscape: Review strategic developments in the drug discovery market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.